Full-Time

Associate Director, Data/AI Solution Architect

US Commercial Digital Marketing

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical firm developing HIV/AIDS therapies

Compensation Overview

$169k - $218.7k/yr

+ Discretionary annual bonus + Discretionary stock-based long-term incentives

Company Historically Provides H1B Sponsorship

Raleigh, NC, USA

Hybrid

Hybrid-eligible; the posting does not specify the required number of on-site days.

Bachelor's, Master's, PhD

Category
Sales & Solution Engineering (1)
Required Skills
Data Science
Machine Learning
Data Engineering
AWS
Data Governance
Databricks

Get referred to Gilead Sciences

See people who can refer or advise you

Requirements
  • A Bachelor's Degree and ten years of experience, or a Master's Degree and eight years of experience, or a PhD and two years of experience.
  • Significant experience designing data, analytics, and artificial intelligence solutions, with demonstrated depth in architecture and advanced analytics.
  • Proven experience with predictive modeling, machine learning, and analytics solution design; hands-on experience on AWS and Databricks platforms is strongly preferred.
  • Deep understanding of emerging data and artificial intelligence architectures, platforms, tools, and analytics stacks.
  • Previous experience designing solutions across Life Sciences Commercial Marketing and Sales digital platforms, content, or engagement data is required.
  • Ability to translate complex business needs into technical designs and influence stakeholders without direct authority.
  • Strong communication, collaboration, and stakeholder management skills, with the ability to engage effectively with both technical and non-technical partners.
Responsibilities
  • Determine end-to-end data and artificial intelligence solution architecture for digital marketing use cases, including predictive modeling and advanced analytics across the digital content lifecycle.
  • Design how solutions are delivered, including data flows, modeling approaches, integration patterns, and analytics outputs on AWS and Databricks platforms.
  • Apply enterprise and domain architecture and tool standards, while providing input to inform and evolve those standards.
  • Evaluate build-versus-buy options and recommend platforms, tools, and frameworks aligned with enterprise strategy.
  • Develop solution blueprints and lifecycle maps to guide implementation from data creation through insight generation.
  • Define data quality, observability, and validation expectations for Commercial Digital data products, ensuring data is complete, accurate, timely, trusted, and fit for analytics, artificial intelligence, and downstream business decision-making.
  • Ensure data products and solution designs include clear business context, ownership, lineage, metadata, cataloging, sensitivity classification, refresh frequency, usage guidance, and traceability from source data through transformation, model input and output, insight generation, and business action.
  • Develop and maintain data architecture artifacts, including source-to-target flows, integration patterns, canonical data models, semantic layers, master and reference data dependencies, business rules, key entities, metrics, and downstream consumption patterns.
  • Partner with Enterprise Architecture and platform teams to maintain application, capability, integration, lifecycle, and data-flow mappings in the enterprise system of record, supporting architecture reviews, impact assessments, technology rationalization, and alignment with enterprise standards.
  • Partner with Capability Leads and Product Owners to translate business capability needs into well-structured solution designs, data architecture, platform dependencies, and technical delivery guardrails.
  • Support the artificial intelligence, data science, and data engineering teams by defining the data architecture, feature inputs, model integration patterns, traceability, and operational data requirements needed to move artificial intelligence use cases from concept to production.
  • Ensure artificial intelligence solution designs include the required data readiness, context, lineage, integration, governance, monitoring, and handoff requirements so models and insights can be deployed, maintained, and reused across Commercial Digital capabilities.
  • Ensure solution designs support scalability, reusability, performance, security, and governance.
  • Maintain clear technical documentation, design artifacts, and architectural diagrams to support delivery and long-term maintainability.
  • Create inclusion by modeling inclusion and embedding the value of diversity in the way teams are managed.
  • Develop talent by understanding employees' skills, experience, aspirations, and potential; coaching current performance and future potential; and ensuring employees receive feedback and insight needed to grow and develop.
  • Empower teams by connecting them to the organization, aligning goals and objectives, holding them accountable, removing barriers, and connecting them to the broader ecosystem.
Desired Qualifications
  • Hands-on experience on AWS and Databricks platforms.

Gilead Sciences discovers, develops, and markets medicines to treat HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Its products reach patients globally after regulatory approval, sold through doctors, hospitals, and pharmacies. The company relies on a large, diverse R&D pipeline and strategic partnerships to expand its therapies and reach, including collaborations like SAP Ariba to improve sourcing. Its goal is to improve health equity by expanding access to medicines and promoting sustainable healthcare practices worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 product sales excluding Veklury rose 10%, and guidance increased to $30.4 billion.
  • Yeztugo reached a $1 billion annual run rate with strong patient retention by August 2026.
  • Anito-cel’s FDA PDUFA date is December 23, 2026, creating a near-term oncology catalyst.

What critics are saying

  • HIV still generated nearly three-quarters of quarterly product sales in Q2 2026.
  • Cell therapy sales fell 14% in Q2 2026, showing Kite faces harsh competition.
  • Arcellx integration cut 192 jobs, signaling execution risk and post-deal disruption through 2027.

What makes Gilead Sciences unique

  • Gilead owns HIV leadership with Biktarvy, Descovy, and Yeztugo driving 2026 growth.
  • The August 2026 Arcellx acquisition strengthens Gilead’s CAR-T position for anito-cel.
  • Gilead’s California Supreme Court victory protects its innovation model across future drug portfolios.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 24th, 2026
Gilead posts $11B loss on pipeline acquisitions despite 10% product sales growth

Gilead Sciences reported strong commercial performance in Q2 2026, with product sales excluding Veklury rising 10% to $7.6 billion. HIV revenue grew 12% to $5.7 billion, led by Biktarvy at $3.8 billion and Descovy at $967 million. Despite this growth, the company posted one of its largest quarterly losses due to over $11 billion in acquired research and development expenses. These acquisitions included Arcellx, which gives Gilead full control of anito-cel, a CAR-T treatment for multiple myeloma pending FDA approval by December 2026. The company raised its 2026 product-sales guidance to $30.1–$30.4 billion. Gilead also reported encouraging progress beyond HIV, with liver-disease revenue up 10% and Trodelvy breast-cancer treatment sales rising 26% to $457 million.

Yahoo Finance
Aug 23rd, 2026
Gilead's HIV sales surge 12% to $5.7B, but franchise accounts for 75% of total revenue

Gilead Sciences reported strong fiscal Q2 2026 results, with total revenue rising 10% year-over-year to approximately $7.8 billion. The growth was primarily driven by its HIV franchise, including Biktarvy and newly launched Yeztugo. HIV product sales rose 12% to $5.7 billion, representing nearly three-quarters of quarterly product sales. Descovy sales increased 48% to $967 million, whilst Biktarvy sales grew 7% to $3.8 billion. Yeztugo generated $232 million, up substantially from $15 million in the prior-year period. The company's liver disease portfolio sales rose 10% to $877 million. However, cell therapy sales declined 14% to $417 million, reflecting competitive pressure. Gilead recorded an $11.2 billion quarterly loss due to acquired research and development expenses, including $7.0 billion for the Arcellx acquisition.

Ticker Report
Aug 18th, 2026
MidFirst Bank Makes New $810,000 Investment in Gilead Sciences, Inc. $GILD

MidFirst Bank acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 6,414 shares of the biopharmaceutical company’s stock, valued at approximately $810,000. A number of other hedge funds and other institutional investors […]

Yahoo Finance
Aug 16th, 2026
Gilead Sciences down 11.3% in six months as revenue growth disappoints at 2.7% CAGR

Gilead Sciences' shares have fallen 11.3% to $137.77 over the past six months, contrasting with the S&P 500's 13.1% gain. The biopharmaceutical company has shown disappointing long-term performance, with revenue growing at just 2.7% annually over five years. The company's profitability metrics have deteriorated significantly. Its adjusted operating margin decreased by 34.2 percentage points over the past five years, landing at 9.7% for the trailing 12 months. Earnings per share declined by 15.4% annually during the same period, indicating reduced profitability as the company expanded. Despite trading at a relatively fair valuation of 14.9× forward price-to-earnings ratio, analysts suggest limited upside potential compared to downside risk.

Yahoo Finance
Aug 13th, 2026
Gilead Sciences beats Q2 estimates with $7.8B revenue as PrEP sales top $1B for first time

Gilead Sciences reported strong Q2 results, with revenue of $7.80 billion, beating analyst estimates of $7.35 billion. The 10.2% year-on-year growth was driven by its HIV franchise, particularly Biktarvy and the PrEP segment, alongside advances in oncology and liver disease treatments. CEO Daniel O'Day highlighted that quarterly PrEP sales doubled year-on-year, exceeding $1 billion for the first time. New product launches, including Trodelvy in breast cancer and Livdelzi in liver disease, contributed to the results. The company raised its full-year revenue guidance to $30.25 billion at the midpoint and increased adjusted EPS guidance by 44.1%. During the earnings call, analysts questioned management about prescription trends, product strategies, revenue diversification, regulatory interactions, and the impact of US insurance changes on Biktarvy's growth.